ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 2423 • ACR Convergence 2024

    Associations Between Cytometric Interferon Signature and Clinical Response in a Cohort of Anifrolumab-treated Patients with Lupus

    Alice Horisberger1, Katharina Shaw2, Eilish Dillon3, Kathryne Marks4, Rochelle Castillo5, Ifeoluwakiisi Adejorin6, Kimberly Hashemi4, Karen Costenbader7, Avery LaChance8, Ruth Ann Vleugels5 and Deepak Rao1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Perelman School of Medicine at the University of Pennsylvania, Merion Station, PA, 3University of Massachusetts Boston, Yarmouth, MA, 4Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 8Brigham and Women's Hospital, Jamaica Plain, MA

    Background/Purpose: Anifrolumab, a monoclonal antibody targeting type I interferon (IFN-I) receptor subunit 1, was recently approved for the treatment of systemic lupus erythematosus (SLE) and…
  • Abstract Number: 2440 • ACR Convergence 2024

    Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics

    Irene Carrión-Barberà1, Tarek Carlos Salman Monte:2, Laura Triginer3, María García-Villanueva4, Sandra Garrote Corral5, Anne Riveros Frutos6, Judit Font7, María Galindo-Izquierdo8, Carlos de Frías Polo9, Jorge Juan Fragío Gil10, Clara Moriano11, Elvira Díez Álvarez12, Pilar Bernabéu13, Paloma Vela-Casasempere14, Josefina Cortés-Hernández15, Sebastián Sandoval Moreno16, Javier Narvaez-García17, Andrea Hernández-Martín18, Berta Paula Magallares19, María Piqueras García20, Carlos Marras21, Consuelo Ramos22, Jose Alfredo Gomez-Puerta23, Beatriz Frade-Sosa24, Ana Fernández-Ortiz25, Angel Garcia-Aparicio26, Irene Altabás-González27, Samuel Hernández-Baldizón28, Inmaculada Ros-Vilamajó29, Silvia García Cirera30, Marta Garijo Bufort31, Luis Sala32, Julia Martínez-Barrio33, José Rosas-Gómez de Salazar34, Sergi Heredia35, Vicenç Torrente-Segarra36, Anahy Maria Brandy-Garcia37, Natividad del Val del amo38, Concepción Fito-Manteca38, Jaime Calvo-Alen39, José María Pego-Reigosa40 and Íñigo Rúa-Figueroa41, 1Hospital del Mar, Barcelona, Spain, 2Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 3Hospital del Mar Research Institute, Barcelona, Spain, 4Hospital Ramón y Cajal, MADRID, Madrid, Spain, 5Hospital Universitario Ramón y Cajal, Madrid, Spain, 6Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 7Hospital Germans Trias i Pujol, Barcelona, Spain, 8Hospital 12 de Octubre, Madrid, Madrid, Spain, 9Hospital 12 de Octubre, Madrid, Spain, 10Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, 11Hospital León, LEON, Spain, 12Complejo Asistencial Universitario de León, León, Spain, 13Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, 14Hospital General Universitario Alicante, Alicante, Spain, 15Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, 16Hospital Vall d'Hebron, Barcelona, Spain, 17Hospital Universitario de Bellvitge, Barcelona, Spain, 18Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, 19Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain, 20Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 21Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 22Hospital Universitario Virgen de Valme, Sevilla, Spain, 23Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, 24Hospital Clínic, Barcelona, Spain, 25Hospital Universitario de Badajoz, Badajoz, Spain, 26Hospital Universitario de Toledo, Toledo, Spain, 27Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, 28Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 29Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, 30Hospital Parc Taulí, Sabadell, Spain, 31Hospital de Sagunto, Sagunto, Spain, 32Hospital Universitario de Torrejón, Torrejón, Spain, 33Hospital Gregorio Marañón, Madrid, Spain, 34Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, 35Hospital Moisès Broggi, Sant Joan Despí, Spain, 36Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, 37Hospital Germans Trias i Pujol, Badalona, Spain, 38Complejo Universitario de Navarra, Navarra, Spain, 39Hospital Universitario de Araba, Araba, Spain, 40Galicia Health Service (SERGAS), Vigo, Spain, 41Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain

    Background/Purpose: Anifrolumab is a biological treatment with recent approval for systemic lupus erythematosus (SLE), supported by its efficacy in clinical trials. However, data from real…
  • Abstract Number: 2603 • ACR Convergence 2024

    A Human Lupus Gut Pathobiont Accelerates Systemic Inflammation, Autoantibody Production and T Cell Dysregulation

    Gregg Silverman1 and Laurence Morel2, 1NYU Grossman School of Medicine, New York, NY, 2Joe R. & Teresa Lozano Long School of Medicine, San Antonio, TX

    Background/Purpose: The mechanisms by which the gut microbiome contributes to autoimmune pathogenesis remain poorly understood. In lupus patients, more than ten-fold blooms of Ruminococcus gnavus…
  • Abstract Number: PP14 • ACR Convergence 2024

    Support Groups and Chronic Illness: Finding Social Support Among Peers

    Alexandra Blumhorst1 and Estela Mata-Carcamo2, 1Looms for Lupus, Silver Spring, MD, 2Looms for Lupus, Irwindale, CA

    Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…
  • Abstract Number: 0092 • ACR Convergence 2024

    A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis

    Hulya Bukulmez1, Adrienne Dennis2, kristine Highland3 and Steven N. Emancipator4, 1MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, 2MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland, OH, 4Case Western Reserve University, Cleveland, OH

    Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…
  • Abstract Number: 0167 • ACR Convergence 2024

    Epidemiology of Falls in a Diverse Cohort of Adults with SLE

    Laura Plantinga1, Charmayne M. Dunlop-Thomas2, Courtney Hoge3, Jinoos Yazdany4 and C. Barrett Bowling5, 1University of California, San Francisco, San Francisco, CA, 2Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, 3Emory University, Atlanta, GA, 4UCSF, San Francisco, CA, 5Duke University, Durham, NC

    Background/Purpose: While often preventable, falls are a common, costly, and serious outcome in the U.S. population: more than one in four adults ³65 years old…
  • Abstract Number: 0191 • ACR Convergence 2024

    Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care

    Alyssa Howren1, Quan Le Tran1, Sadaf Sediqi1, Saadiya Hawa2, Eleni Linos1, Titilola Falasinnu3, Yashaar Chaichian1 and Julia Simard1, 1Stanford School of Medicine, Stanford, CA, 2Weiss Memorial Hospital, Chicago, IL, 3Stanford School of Medicine, Palo Alto, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune rheumatic disease whose prognosis varies by race and sex. To understand whether the cognitive processes of…
  • Abstract Number: 0353 • ACR Convergence 2024

    Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach

    Joy Buie1, Michael Fisher1, Hannah Tlydsley2, Kristen Backor2 and Karen Costenbader3, 1Lupus Foundation of America, Washington, DC, 2Charles River Associates, San Francisco, CA, 3Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

    Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and…
  • Abstract Number: 0442 • ACR Convergence 2024

    Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus

    Anam Nazir1, Joshua Reed2, Khalid Alghamdi2 and Catherine Ivory1, 1The Ottawa Hospital, Ottawa, ON, Canada, 2The Ottawa Hospital Research Institute, Ottawa, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) affects women of childbearing years and confers an increased risk of pregnancy complications. Risk of adverse events in pregnancy is…
  • Abstract Number: 0618 • ACR Convergence 2024

    Comparison of Cell Type-Specific Polygenic Risk in Systemic Lupus Erythematosus Patient and Healthy Controls

    Liyoung Kim1, Vitor Aguiar2, Daniela Fernandez-Salinas3, Jeffrey Sparks4, Peter Nigrovic1, Joyce Chang2 and Maria Gutierrez-Arcelus2, 1Boston Children's Hospital, Brookline, MA, 2Boston Children's Hospital, Boston, MA, 3Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Polygenic risk scores quantify the composite impact of numerous genetic variants to predict disease risk. However, conventional polygenic risk scores have limitations in revealing…
  • Abstract Number: 0637 • ACR Convergence 2024

    Active Implementation of Low Disease Activity State as Treatment Endpoint in a Large Cohort of Adolescents and Young Adults with Childhood Onset Systemic Lupus Erythematosus

    Ruby Gotch1, Yumna Ahmed1, Robert Wilson1, Ellie Hawkins1 and Coziana Ciurtin2, 1University College London Hospital NHS Trust, London, United Kingdom, 2University College London, London, United Kingdom

    Background/Purpose: Treat-to-target (T2T) strategies are focused on proactive and tailored management of disease activity to minimise damage risk and improve long-term outcomes in SLE across…
  • Abstract Number: 0655 • ACR Convergence 2024

    Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry

    Minjee Park1, Sofia Pedro2, Jean-Francois Ricci1, Kaleb Michaud3 and Patti Katz4, 1Alira Health, Basel, Switzerland, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3University of Nebraska Medical Center, Omaha, NE, 4UCSF, San Rafael, CA

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with diverse symptoms and multisystemic manifestations. Reducing exacerbations (flares), often leading to hospitalization, remains a challenge…
  • Abstract Number: 0673 • ACR Convergence 2024

    BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients

    Yong Yuan1, Shanzhi He2, Wenli Zhang3, Hongyu Zhang4, Vincent M DeStefano5, Masayuki Wada5, Kevin Pinz5, Greg Deener5, Yu Ma6, Min Wang2, Fugui Li7, Ming Hong1, Chanjuan Zou2, Mingxia Wang2, Ling Ding2, Yingwen Liang8, Yupo Ma5 and Weija Wang9, 1Department of Translational Medicine, Zhongshan people's Hospital, Zhongshan, China (People's Republic), 2Department of Rheumatoid Immunology, Zhongshan people's Hospital, Zhongshan, China (People's Republic), 3Department of Hematology, Peking University Shenzhen Hosptial, Shenzhen, China (People's Republic), 4Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China (People's Republic), 5iCell Gene Therapeutics, Inc., Stony Brook, NY, 6iCAR Bio Therapeutics Ltd, Zhongshan, China (People's Republic), 7Department of Translational Medicine. Zhongshan people's Hospital, Zhongshan, China (People's Republic), 8Department of Translational Medicine, Zhongshan's people Hospital, Zhongshan, China (People's Republic), 9Department of Translational Research, Zhongshan people's Hospital, Zhongshan, China (People's Republic)

    Background/Purpose: Medication free complete remission (CR) has been elusive in SLE. An open label investigator-initiated trial (IIT) infused SLE/LN patients with a novel cCAR targeting…
  • Abstract Number: 0897 • ACR Convergence 2024

    Dynamic eQTLs from Activated Human B Cells Suggest Cell-state Dependent Effects for GWAS Risk Variants in BLK

    Yao Fu, David Murphy, Richard Pelikan, Jeniffer Kelly, Kiely Grundahl, Satish Pasula, Kandice Tessneer and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex genetic disease in which B cells play a critical role in pathogenesis. Previous genome-wide association studies (GWAS)…
  • Abstract Number: 1045 • ACR Convergence 2024

    Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) can significantly impact quality of life. This burden extends…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology